Abstract. Vasculitis in systemic lupus erythematosus (SLE) is associated with the deposition of IgG and complement in blood vessel walls. However, it is not known whether immune injury to endothelial cells is a part of this process.
Introduction
Antibody and complement are found within blood vessel walls of patients with systemic lupus erythematosus (SLE)1 and other forms of human vasculitis (1) . Although immune complexes and autoantibodies persist in the systemic circulation of these patients, vascular injury itself is episodic and restricted. The lesions of each classic form of vasculitis have a distinct appearance. They generally affect vessels of a particular size and only certain organs are involved (1) . The reasons for this specificity remain unclear, and the target of immune injury within the vessel wall remains uncertain (2) .
Endothelial cells appear to possess certain characteristics that make them a candidate for immune vascular injury. They have been shown to be important both in presenting antigen to lymphocytes (3) and in regulating lymphocyte migration through vessel walls (4, 5) . In addition, endothelial cells have been shown to express ABH, HLA, D/DR, and endothelialspecific antigens on their cell surface (6) (7) (8) (9) (10) . Moreover, since these cells are in direct contact with circulating antibody, immune complexes, complement, and effectors of cell-mediated immunity, immune injury to endothelial cells may play a role in the pathogenesis of several immune vascular disorders.
Several studies have shown that endothelial injury modifies the expression of endothelial surface antigens and promotes active binding of immune complexes to these cells (11, 12) . However, it is less certain whether uninjured endothelium has the capacity to bind immune complexes or autoantibodies (12) (13) (14) (15) (16) (17) (18) . In this study we asked whether patients with SLE have IgG antibodies or IgG-containing immune complexes that bind to normal human endothelial cells. Because normal endothelium is a nonthrombogenic surface, we also asked whether immune injury caused by IgG and complement would alter the association of endothelial cells with human platelets.
Methods
Endothelial cell culture. Endothelial cells were harvested from human umbilical cord veins by collagenase digestion using established methods (12, 19, 20) . Endothelial cells were grown in medium 199 (Gibco Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Flow Laboratories, Inc., McLean, VA), penicillinstreptomycin-fungizone (Gibco Laboratories) and endothelial cell growth supplement, which was prepared according to the method of Maciag et al. (21) and Booyse et al. (22) . In some experiments endothelial cells were studied in suspension either immediately after isolation or following overnight incubation in conditioned medium. In other experiments, confluent monolayers were prepared by pretreating plastic surfaces with human fibronectin, which had been purified by gelatin affinity chromatography (Difco Laboratories, Detroit, MI) (21) . In these experiments endothelial cells were plated directly onto fibronectin-coated 96-well microtiter plates (Linbro Chemical Co., Hamden, CT), 24-well microtiter plates (Costar Data Packaging, Cambridge, MA), or 100 X 20-mm tissue culture dishes (Falcon Labware, Div. ofBecton, Dickinson & Co., Oxnard, CA). In individual experiments, confluent endothelial cells after 3-5 d in culture were passaged by a 3-5-min exposure to 1% trypsin (Gibco Laboratories) at 37°C and the reaction terminated with an equal volume of soybean trypsin inhibitor (2.5 mg/ml) in medium 199 (Gibco Laboratories). After centrifugation, the cells were divided in thirds and cultured as above (21) . Both the primary cultures and the passaged cells were positive for Factor VIII antigen (23) . For performance of immunofluorescence microscopy, endothelial cells were grown directly on sterile 12-mm2 coverslips (SGA Scientific, Inc., Bloomfield, NJ), washed twice in phosphate-buffered saline (PBS), and fixed for 10 min at 22°C with fresh 2% formaldehyde.
Sources of human IgG. We used several sources of human IgG to sensitize endothelial cells. Sera were obtained from normal healthy volunteers; from three patients with IgG myeloma; from nine patients with thrombotic thrombocytopenic purpura (TTP), before exchange transfusion; and from 27 patients with active SLE, each of whom fulfilled the diagnostic criteria of the American Rheumatism Association. Sera were generally used at a 1:2 dilution. Immune complex-like activity in each serum was assessed by the level of'25I-Clq precipitinsas determined by Dr. David Koffler (Hahnemann Hospital, Philadelphia, PA) (24) .
Purified IgG was prepared from sera by ammonium sulfate precipitation, anion exchange chromatography using quarternary amino ethyl Sephadex, and Sephadex G-200 chromatography (25) Erythrocytes and platelets were isolated either from fresh whole blood or from platelet concentrates (25) . Mononuclear cells were prepared from heparinized whole blood by density gradient centrifugation using lymphocyte separation medium (Litton Bionetics, Kensington, MD). To further purify the mononuclear fraction, the cells were allowed to adhere to 150-cm2 flasks (Corning Glass Works, Corning Medical and Scientific, Corning, NY) for 20 min at 37°C (30) . After exposure to trypsin, the adherent cells were removed from the plastic with a rubber policeman; >95% of these cells showed positive staining for nonspecific esterase. The nonadherent population was further subdivided into T cells and B cells by double rosetting with fresh sheep erythrocytes treated with 2-amino-ethylisothiouranium bromide (31) . To obtain a sufficient mass ofendothelial cells for these studies, primary endothelial cell cultures from -10 donors were subcultured through four passages.
Assessment of endothelial-associated IgG by solid phase radioimmunoassay (RIA). The Endothelial cells in suspension were also incubated at 4VC with several sources of murine monoclonal antibodies and FITC-conjugated goat F(ab')2 anti-mouse F(ab')2 (Tago, Inc.). Murine monoclonal antibodies OKT3 (panagglutinin), OKTl 1 (sheep erythrocyte rosette receptor), OKT9 (transferrin receptor), OKM 1, and OK-Ia-I (D/DR antigen) were obtained from the Ortho Diagnostic Systems, Inc. (Westwood, MA). A2A9 is an IgG2 murine monoclonal anti-platelet antibody that binds to the platelet glycoprotein IIb-IIa complex and competitively inhibits the binding of fibrinogen to stimulated platelets (33) . P3X63 is the nonantibody Ig-secretory product of the parent myeloma cell line. D-1-6, 691, and SK-379 are monoclonal anti-Ia antibodies developed by immunization with melanoma cells and were the gift of Dr. Alonzo Ross (Wistar Institute, Philadelphia, PA). CX-2. 1 is a monoclonal antihuman D/DR antibody prepared against myeloid leukemia cells and was a gift of Dr. James Hoxie (University of Pennsylvania). 63-D-3 (Bethesda Research Laboratories, Bethesda, MD) is a monoclonal antibody that reacts strongly with peripheral blood monocytes and weakly with normal granulocytes. W6/32 (anti-HLA framework) was purchased from Pel-Freeze Biologicals, Rogers, AK. B1, the anti-B cell antibody, and J5, the antibody reactive with the common acute lymphocytic leukemia antigen, were purchased from Coulter Electronics, Inc., Hialeah, FL. Rabbit anti-mouse Ia alloantiserum was obtained from Cedarlane Laboratories, Inc. (Hornby, Ontario, Canada).
Endothelial cells exposed to various human, rabbit, and murine Ig were reacted with the corresponding FITC-conjugated anti-Ig and analyzed on an Ortho Spectrum III fluorescence cell analyzer (Ortho Diagnostic Systems, Inc.) by the method of Ip et al. (34) using the 1129-66 program designed for large cells, thereby excluding normal circulating leukocytes (Fig. 2 A) . Positive and negative regions were defined using P3X63 as a negative control and adjusting the analyzer threshold such that <1% of the cells were considered positive. Using this program, only a single population ofcells positive for Factor VIII antigen was identified on the basis of the right angle and the narrow forward light scattering properties of the individual cells. The extent of binding of FITC-conjugated anti-Ig to this cell population was determined by quantitating the magnitude ofthe green fluorescence signal (34) . Approximately 2,000 cells were analyzed in each experiment. Both the percentage of cells showing increased fluorescence above background and the degree of fluorescence, expressed as the "mean positive channel," were determined (34) .
The binding of IgG to endothelial cells was confirmed by fluorescence microscopy. Each source of human IgG was directly conjugated with FITC, isomer I (Sigma Chemical Co.), to a molar ratio of FITC to IgG ofbetween 3 and 4:1 by established methods (35) . Endothelial cells were fixed with 2% formalin for 10 min at 220C. After three washes in PBS, the cells were incubated with 50 gl ofconjugated immunoglobulin (0.1-1.0 mg/ml) for 45 min at 370C. The cells were washed and the binding was assessed using the Zeiss MC-63 fluorescence microscope (Carl Zeiss, Inc., New York).
We also performed studies using unfixed endothelial cells to determine if IgG would bind to the surface of the endothelium. Fluoresbrite fluorescent monodisperse carboxylated microspheres (0.84 gm in diameter) were obtained from Polysciences, Inc., Warrington, PA. 1 ml of washed beads, containing -108 spheres, was incubated with 1 mg of HA-IgG or I mg of human serum albumin at 40C for 18 h and resuspended in Dulbecco's PBS containing 3% human serum albumin. The efficiency ofcoupling protein to these beads was >95% as measured by the optical density of the residual unbound protein. Endothelial monolayers on fibronectin-covered glass coverslips were washed twice with the albumincontaining buffer, incubated with 30 Ml of the protein-coated beads for 30 min at 37°C, and thoroughly washed to remove unbound beads. The cells were then fixed with 1% fresh formaldehyde, washed and photographed in phase contrast and for immunofluorescence as detailed above. We further assessed the integrity of the endothelial cell surface membrane using FITC-conjugated rabbit IgG anti-rat cytoplasmic myosin (gift of Dr. Vivian Nachmias, Department of Anatomy, University of Pennsylvania) (36) . Human endothelial cellspermeabilized in 1% acetone showed intense cytoplasmic fluorescence following incubation with this antibody. In contrast, the unfixed endothelial cells used in this study, Secretion of prostaglandin I2 (PGI2); adherence of platelets. The release of PGI2 from endothelial cells was assessed by measuring its stable metabolic end product 6-keto-prostaglandin Fla (6-keto-PGFI.).
Primary endothelial cultures were incubated with bovine thrombin (Parke-Davis, Co., Div. of Warner-Lambert, Inc., Morris Plains, NJ) or a source of human IgG for 10-120 min. The supernatant was harvested and the level of 6-keto-PGFIa was quantitated by a competitive RIA (New England Nuclear).
The adherence ofplatelets to endothelial monolayers was performed by a modification of published methods (37) . Human platelets were isolated in acid citrate dextrose (ACD) and radiolabeled with 5"Cr for 30 min at 37°C ("Cr-Na, New England Nuclear) in 10 ml Tyrode's buffer pH 7.2 to which 0.4 ml ACD had been added. The unincorporated "Cr was removed by washing two times in ACD/Tyrode's buffer, and the labeled platelets were resuspended at I X 10' cells/ml and added to washed endothelial monolayers, previously exposed to thrombin (0.1-2.0 U/ml) or a source of human IgG for 10-60 min. After incubation with 5'Cr-labeled platelets (1 ml) at 37°C for 30-120 min, the monolayer was again vigorously washed, and the presence ofadherent platelets was assessed by phase-contrast microscopy. The endothelial monolayer and adherent platelets were then removed by cotton applicator swabs, which were counted for gamma emission as described above. Monolayers were also fixed with 2% gluteraldehyde and processed by critical endpoint drying. Scanning electron microscopy was then performed with an SEM 500 scanner (Phillips Electronic Instruments, Inc., Mahwah, NJ) (12 a
We also studied sera from two patients who had rejected renal allografts, a condition in which endothelial antibodies have been previously demonstrated to occur (6-10). Both sera also had high titers of anti-HLA antibodies. These sera deposited increased amounts of IgG on endothelial cells, comparable to the amounts deposited by SLE sera (Fig. 1) . Sera from eight of nine untransfused patients with newly diagnosed TTP caused only a modest increase in *SPA binding (P = 0.1).
Because binding of IgG to endothelial cells could be a property of cells in culture, studies were carried out with freshly isolated endothelial cells in suspension, using the Ortho Spectrum III fluorescence analyzer. Incubation of endothelial cell suspensions with normal IgG led to the deposition ofsmall amounts of IgG, as had been observed with monolayers. Mechanism of IgG binding SLE sera were further studied to determine whether the IgG associated with endothelial cells was monomeric (7S) antibody or higher molecular weight fractions, such as immune complexes.
The monomeric (7$) IgG fractions from two SLE and two normal sera were separated from complexed IgG by Sephadex G-200 chromatography. These 7S fractions deposited >80% as much IgG as was deposited on endothelial cells by the whole serum from which these 7S fractions were obtained (Fig. 4) . Similar results were observed when these sera were fractionated following sucrose density ultracentrifugation (data not shown).
The F(ab')2 fragments of SLE-IgO or normal IgG also deposited -80% as much IgG on endothelial cells as the native IgG molecule (data not shown). In addition, at each concentration used, the binding of F(ab')2 molecules to endothelial cells was greater when they were prepared from SLE-IgG than when they were prepared from normal IgG (Fig. 5) . Therefore, binding of 7S SLE-IgG is not mediated primarily via an Fc receptor. Rather, IgG molecules in SLE sera bind to endothelial cell antigens predominantly in the form of monomeric endothelial antibodies.
However, a small amount of IgG found in the higher molecular weight fractions (>7S) of SLE sera (present in the void volume of the Sephadex G-200 column) also binds to the endothelium (Fig. 4) . This may represent immune complexes.
To further study the interaction of immune complexes with endothelial cells, we examined the binding of HA-IgG to endothelial cell monolayers (Fig. 6) serum caused increased quantities ofC3 to bind to the endothelial cell surface, as well (Fig. 8) . In contrast, incubation ofendothelial cells with normal serum alone caused the deposition of only small amounts of C3 (Fig. 8) . The (Fig. 9) . The capacity of SLE sera to deposit IgG on endothelial cells was not removed by preincubation with erythrocytes, platelets, or T cells. In contrast, both B cells and monocytes removed appreciable antiendothelial cell activity from the two SLE sera tested (Fig. 9) . Similar results were obtained when the adsorption studies were repeated using F(ab')2 molecules to exclude the possibility that IgG was adsorbed by the Fc receptors on B cells or monocytes.
Since D/DR antigens are present on B cells and monocytes, we looked for the presence of DR on endothelial cells using both heterosera and monoclonal antibodies (Table I) (Table II) . Secretion ofPGI2. Endothelial cells secrete a small, but detectable amount of PGI2, and there is little binding of platelets to undisturbed endothelium. Binding of heat-aggregated IgG to endothelial cells caused a dose-dependent release of6-keto-PGFIa (Fig. 10) . At high concentrations of HA-IgG, the amount of 6-keto-PGFI, released was comparable to that released using thrombin as a stimulus. The IgG fraction of sera from two SLE patients also caused increased PGI2 release when compared with equivalent concentrations of normal monomeric IgG. Endothelial cells secreted PGI2 following a 10-min exposure to thrombin. In contrast, HA-IgG caused a progressive increase in PGI2 release over 2 h (data not shown).
Endothelial morphology and adherence ofplatelets
Endothelial cells grown as monolayers retained their cobblestone appearance and remained contiguous following the addition of either normal IgG or normal serum (Fig. 11 A) . Endothelial cells also remained adherent following exposure to SLE-IgG or HA-IgG. However, the cells separated from each other, with filamentous membrane fragments remaining adherent to the monolayer (Fig. 11 B) . Eventually, the cells assumed a rounded appearance (data not shown).
We observed little binding of platelets to cultured endothelial monolayers (Fig. 12) . Platelet adherence was not increased by addition of normal monomeric IgG, normal sera or myeloma sera to the endothelium. In contrast, sensitization of the endothelium with HA-IgG caused a dose-dependent increase in platelet adherence, comparable in extent to that caused by thrombin (Fig. 12) . Similarly, sera from 13 of 20 patients with active SLE increased platelet binding above the levels observed with normal serum (mean + 2 SD). The IgG fraction from two SLE patients studied also enhanced platelet binding (data not shown). Scanning electron microscopy confirmed the close physical association between the adherent platelets and the endothelial cells following sensitization of the latter with IgG (Fig. 11) .
Discussion
Vascular endothelial cells form a barrier that may protect the vessel wall from the damaging effect of a variety of circulating plasma components. For example, during a normal immune In this study we did not attempt to correlate this serum activity with clinical involvement of specific organs. However, this activity was no longer detectable when patients attained a clinical remission. SLE sera and its IgG fraction also fixed appreciable amounts of C3 to the endothelial cell surface. Furthermore, following interaction with SLE-IgG, the endothelial monolayer was disrupted. Individual cells lost contact with neighboring cells and assumed a rounded appearance. SLE-IgG caused secretion of PGI2 from the endothelium and platelets now adhered diffusely to the injured monolayer. The ability of SLE sera to deposit IgG on endothelial cells was found predominantly in the 7S fraction, and F(ab')2 fragments of SLE-IgG retained antiendothelial activity. This suggests that the activity in SLE sera is primarily due to IgG anti-endothelial cell antibody. However, as noted below, a small amount of activity was also found in the higher molecular weight fractions, compatible with a lesser role for circulating immune complexes in causing endothelial injury.
In contrast, endothelial cells bound only small amounts of normal IgG and C3. Such binding may represent low levels of IgG complexes in normal serum but more likely represents naturally occurring antibodies against blood group or tissuespecific antigens, previously identified on endothelial cells (6) (7) (8) (9) (10) . However, neither monomeric normal IgG nor normal serum appeared to damage the endothelial cells in vitro. The endothelial monolayers remained intact following exposure to normal serum. Adherence of normal platelets to endothelial cells was not observed. Furthermore, neither normal IgG nor normal serum caused the endothelial cells to secrete PGI2. (17, 46) . Furthermore, at concentrations of HA-IgG found in SLE sera, endothelial-bound HA-IgG activated the complement system on the endothelial cells, disrupted the monolayer, initiated PGI2 secretion and caused the monolayer to be covered with adherent platelets. Therefore, our data indicate that SLE sera injure venous endothelial cells in vitro by depositing both antiendothelial antibodies and IgG-containing immune complexes on the surface ofthese cells. It should be noted that these studies using the SPA radioimmunoassay permitted the detection of immune complex deposition, whereas studies in our laboratory (12) and others (11, 13) using erythrocyte rosettes as the assay tool, were unable to detect the binding of complexed IgG by endothelial cells. The presence of anti-endothelial antibodies may not be restricted to patients with SLE. We also observed that sera from two patients who had rejected renal allografts deposited increased amounts of IgG on endothelial cells. Antibodies to endothelial cells have recently been implicated in the development of experimental and clinical allograft rejection (6) (7) (8) (9) (10) 47) . The ability to rapidly determine the presence of anti-renal endothelial cell antibodies in the sera of potential recipients by the techniques described, may help improve donor transplant selection. In addition, our findings are compatible with the recently reported finding of anti-endothelial antibodies or IgG-containing immune complexes in the sera of some patients with TTP (48); however, the titers of activity in most sera of patients with TTP were below those found in patients with active SLE. Finally, IgG and IgM autoantibodies to intermediate filaments and other cytoplasmic antigens within endothelial cells have been noted in a wide variety of disorders and may be present in some normal sera as well (49) (50) (51) . However, these antibodies, which are evident following disruption of the outer cell membrane appear to bear no direct relationship to the surface antibodies in SLE that we describe.
Immune injury to endothelial cells by either antibody or by immune complexes caused the adherence of normal platelets. This may have been due to the exposure of additional binding sites for Factor VIII antigen or new determinants that promote platelet adherence. Alternatively, surface-bound IgG may have served as a bridge between the endothelium and the Fc receptors on human platelets. Regardless of which mechanism was operative, the secretion of PGI2 following immune injury in vitro was insufficient to completely prevent platelet adherence. Similar observations have been made following thrombin-mediated endothelial injury (37) . Surface-bound IgG may also serve to localize leukocytes to vascular tissues, as occurs in both acute and chronic vasculitis in man (1 
